According to BioIntel360, diabetes market in Canada is expected to grow by 12.1% on annual basis to reach US$6,977.2 million in 2025. The diabetes market in the country has experienced robust growth...
According to BioIntel360, diabetes market in Canada is expected to grow by 12.1% on annual basis to reach US$6,977.2 million in 2025. The diabetes market in the country has experienced robust growth during 2020-2024, achieving a CAGR of 12.9%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 10.0% during 2025-2029. By the end of 2029, the diabetes market is projected to expand from its 2024 value of USD 6,226.0 million to approximately USD 11,372.1 million. Key Trends and Drivers in Canada The Canadian market is experiencing significant shifts, with increased CGM adoption, digital integration, advanced therapeutic systems, and evolving regulatory support. These trends will intensify over the next 2–4 years, shaping clinical practices and reimbursement structures across provincial healthcare systems. Expand Continuous Glucose Monitoring Usage • Canadian healthcare systems are broadening the use of continuous glucose monitoring (CGM) devices across several provinces. Provincial pilot programs in regions such as Ontario and British Columbia are incorporating CGM into routine diabetes care. • Adjustments in provincial reimbursement policies and recent clinical studies from Canadian health agencies support wider CGM use. Recent publications have highlighted a shift in clinical practice toward data-driven patient monitoring. • The adoption of CGM is expected to intensify as more provinces expand coverage and integrate real-time data into care protocols. Enhanced patient monitoring may improve diabetes management outcomes over the medium term. Integrate Digital Health Solutions for Diabetes Management • Digital health platforms that support remote monitoring and telemedicine are increasingly integrated into diabetes management in Canada. Several regional healthcare systems have initiated digital dashboards to consolidate patient data for clinical decision-making. • Government initiatives to improve telehealth services and recent shifts in healthcare delivery models are driving digital integration. Recent publications underscore provincial health ministries' investments in digital infrastructure. • The integration of digital tools is projected to grow, supporting real-time care adjustments and enhanced data sharing among providers. This trend is expected to intensify as digital health reshapes chronic disease management. Advance Therapeutic Delivery Systems • Advanced therapeutic devices such as smart insulin pens and connected insulin pumps are being tested in clinical settings across Canada. Pilot programs in select provinces have assessed these devices for precise dosing and improved treatment adherence. • Recent technological improvements and research findings from Canadian institutions support the development of these systems. Funding and innovation incentives from provincial health programs are fostering the introduction of these therapeutic tools. • Adoption will likely grow as clinical evidence and reimbursement models evolve, integrating these devices into standard practice. The trend is expected to intensify gradually, influencing treatment protocols in diabetes care. Regulatory and Reimbursement Models • Regulatory bodies in Canada are updating guidelines and reimbursement policies to accommodate new diabetes devices and therapeutics. Recent policy documents have outlined pathways for including digital health and connected devices in public healthcare programs. • Broader cost-containment strategies and ongoing evaluations of digital health effectiveness drive regulatory adjustments. Publications from provincial health ministries and Health Canada provide context for these evolving frameworks. • Clearer regulatory and reimbursement models are anticipated to further support device integration and market expansion. These changes are expected to have a progressive impact, offering more defined channels for innovation in diabetes management. Competitive Landscape in Canada The Canadian diabetes devices and therapeutics market is characterized by a blend of multinational leaders and emerging technology-driven entrants. Recent strategic partnerships, mergers, and acquisitions indicate a move toward more integrated care solutions. In the coming years, competitive dynamics are expected to intensify, driven by consolidation and a focused shift toward digital integration and regulatory compliance. Current Market Conditions • The diabetes devices and therapeutics market in Canada comprises established multinational firms and emerging domestic players. A structured healthcare system with defined reimbursement pathways supports traditional and digital solutions. Key Competitors and New Entrants • Several longstanding multinational companies hold significant market share. They offer a range of devices, from continuous monitoring systems to therapeutic delivery tools, and maintain strategic relationships with provincial healthcare agencies. • New market entrants, including technology-focused startups, are introducing digital health solutions that target remote monitoring and data integration. Recent publications indicate that pilot programs in provinces allow these entrants to demonstrate value. Review Strategic Partnerships and Corporate Developments • Recent publications detail partnerships where established companies collaborate with digital health startups to enhance device connectivity and patient data analytics. Mergers and acquisitions have been noted as firms consolidate technical expertise and broaden their market offerings within the Canadian context. • These strategic developments reshape the market by promoting integrated care solutions and streamlined regulatory compliance. Collaborative efforts are aligning product innovation with provincial healthcare priorities. Future Competitive Dynamics (2–4 Years) • The competitive landscape is expected to evolve as strategic partnerships and consolidation efforts deepen. Companies will likely increase investments in digital health integration, balancing established market leaders with nimble entrants. • Over the next 2–4 years, market consolidation and technology-driven innovation are anticipated to further define competitive positioning, with clear implications for patient management strategies. This report provides a detailed data-centric analysis of the diabetes industry in Canada, covering market opportunities and analysis across a range of diagnosis and monitoring devices, therapeutics, domains. With over 50+ KPIs at the country level, this report provides a comprehensive understanding of diabetes market dynamics, market size and forecast, and market share statistics. BioIntel360’s research methodology is based on industry best practices. Its unbiased analysis leverages a proprietary analytics platform to offer a detailed view of emerging business and investment market opportunities.
This report provides an in-depth, data-centric analysis of the Canada diabetes devices and therapeutics market 2020-2029. Below is a summary of key market segments: Diabetes Devices and Therapeutics Market Share by Category • Diagnosis and Monitoring Devices • Therapeutics Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices • Blood Glucose Monitoring Devices • Insulin Delivery Devices • Diabetes Management and Mobile Applications • Artificial Pancreas Devices Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices • Self-Monitoring Blood Glucose Devices • Continuous Blood Glucose Monitoring Devices • Test Strips • Lancets Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices • Insulin Pumps • Insulin Pens • Insulin Syringes Diabetes Devices and Therapeutics Market Share by Therapeutics • Oral Anti-Diabetic Drugs • Insulin • Non-Insulin Injectable Drugs • Combination Drugs Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs • Alpha-Glucosidase Inhibitors • DPP-4 Inhibitors • SGLT-2 Inhibitors Diabetes Devices and Therapeutics Market Share by Insulin • Basal or Long-Acting • Bolus or Fast-Acting • Traditional Human Insulin Drugs • Insulin Biosimilars Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs • GLP-1 Receptor Agonists • Amylin Analogue Diabetes Devices and Therapeutics Market Share by Combination Drugs • Combination Insulin • Oral Combination Diabetes Devices and Therapeutics Market Share by Route of Administration • Subcutaneous • Intravenous • Others Diabetes Devices and Therapeutics Market Share by Type of Diabetes • Type 1 Diabetes • Type 2 Diabetes Diabetes Devices and Therapeutics Market Share by Distribution Channels • Online Pharmacies • Hospital Pharmacies • Retail Pharmacies Diabetes Devices and Therapeutics Market Share by End User • Hospitals • Diabetes Clinics • Homecare
• Comprehensive understanding of market structure and dynamics: Gain a detailed view of the diabetes devices and therapeutics market, including category-level segmentation (Diagnosis & Monitoring Devices and Therapeutics) and sub-segmentation by product type, route of administration, type of diabetes, distribution channel, and end user. • Identify high-growth segments and strategic investment areas: Use segment-wise market sizing and forecasting to identify opportunities in areas such as continuous glucose monitoring, insulin delivery technologies, oral anti-diabetic drugs, and biosimilars. Tailor your market entry or expansion strategies accordingly. • Benchmark performance across distribution and care settings: Access share analysis across online, hospital, and retail pharmacies, and evaluate usage patterns across hospitals, diabetes clinics, and homecare to support channel-specific planning and resource allocation.
1 Canada Diabetes Devices and Therapeutics Market Size and Forecast, 2020-2029 2 Canada Diabetes Devices and Therapeutics Market Share by Category, 2020-2029 2.1 Canada Diabetes Devices and Therapeutics Market Size by Diagnosis and Monitoring Devices, 2020-2029 2.2 Canada Diabetes Devices and Therapeutics Market Size by Therapeutics, 2020-2029 3 Canada Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices, 2020-2029 3.1 Diabetes Devices and Therapeutics Market Size by Blood Glucose Monitoring Devices, 2020-2029 3.2 Diabetes Devices and Therapeutics Market Size by Insulin Delivery Devices, 2020-2029 3.3 Diabetes Devices and Therapeutics Market Size by Diabetes Management and Mobile Applications, 2020-2029 3.4 Diabetes Devices and Therapeutics Market Size by Artificial Pancreas Devices, 2020-2029 4 Canada Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices, 2020-2029 4.1 Diabetes Devices and Therapeutics Market Size by Self-Monitoring Blood Glucose Devices, 2020-2029 4.2 Diabetes Devices and Therapeutics Market Size by Continuous Blood Glucose Monitoring Devices, 2020-2029 4.3 Diabetes Devices and Therapeutics Market Size by Test Strips, 2020-2029 4.4 Diabetes Devices and Therapeutics Market Size by Lancets, 2020-2029 5 Canada Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices, 2020-2029 5.1 Diabetes Devices and Therapeutics Market Size by Insulin Pumps, 2020-2029 5.2 Diabetes Devices and Therapeutics Market Size by Insulin Pens, 2020-2029 5.3 Diabetes Devices and Therapeutics Market Size by Insulin Syringes, 2020-2029 6 Canada Diabetes Devices and Therapeutics Market Share by Therapeutics, 2020-2029 6.1 Diabetes Devices and Therapeutics Market Size by Oral Anti-Diabetic Drugs, 2020-2029 6.2 Diabetes Devices and Therapeutics Market Size by Insulin, 2020-2029 6.3 Diabetes Devices and Therapeutics Market Size by Non-Insulin Injectable Drugs, 2020-2029 6.4 Diabetes Devices and Therapeutics Market Size by Combination Drugs, 2020-2029 7 Canada Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs, 2020-2029 7.1 Diabetes Devices and Therapeutics Market Size by Alpha-Glucosidase Inhibitors, 2020-2029 7.2 Diabetes Devices and Therapeutics Market Size by DPP-4 Inhibitors, 2020-2029 7.3 Diabetes Devices and Therapeutics Market Size by SGLT-2 Inhibitors, 2020-2029 8 Canada Diabetes Devices and Therapeutics Market Share by Insulin, 2020-2029 8.1 Diabetes Devices and Therapeutics Market Size by Basal or Long-Acting, 2020-2029 8.2 Diabetes Devices and Therapeutics Market Size by Bolus or Fast-Acting, 2020-2029 8.3 Diabetes Devices and Therapeutics Market Size by Traditional Human Insulin Drugs, 2020-2029 8.4 Diabetes Devices and Therapeutics Market Size by Insulin Biosimilars, 2020-2029 9 Canada Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs, 2020-2029 9.1 Diabetes Devices and Therapeutics Market Size by GLP-1 Receptor Agonists, 2020-2029 9.2 Diabetes Devices and Therapeutics Market Size by Amylin Analogue, 2020-2029 10 Canada Diabetes Devices and Therapeutics Market Share by Combination Drugs, 2020-2029 10.1 Diabetes Devices and Therapeutics Market Size by Combination Insulin, 2020-2029 10.2 Diabetes Devices and Therapeutics Market Size by Oral Combination, 2020-2029 11 Canada Diabetes Devices and Therapeutics Market Share by Route of Administration, 2020-2029 11.1 Diabetes Devices and Therapeutics Market Size by Subcutaneous, 2020-2029 11.2 Diabetes Devices and Therapeutics Market Size by Intravenous, 2020-2029 11.3 Diabetes Devices and Therapeutics Market Size by Others, 2020-2029 12 Canada Diabetes Devices and Therapeutics Market Share by Type of Diabetes, 2020-2029 12.1 Diabetes Devices and Therapeutics Market Size by Type 2 Diabetes, 2020-2029 12.2 Diabetes Devices and Therapeutics Market Size by Type 1 Diabetes, 2020-2029 13 Canada Diabetes Devices and Therapeutics Market Share by Distribution Channels, 2020-2029 13.1 Diabetes Devices and Therapeutics Market Size by Online Pharmacies, 2020-2029 13.2 Diabetes Devices and Therapeutics Market Size by Hospital Pharmacies, 2020-2029 13.3 Diabetes Devices and Therapeutics Market Size by Retail Pharmacies, 2020-2029 14 Canada Diabetes Devices and Therapeutics Market Share by End User, 2020-2029 14.1 Diabetes Devices and Therapeutics Market Size by Hospitals, 2020-2029 14.2 Diabetes Devices and Therapeutics Market Size by Diabetes Clinics, 2020-2029 14.3 Diabetes Devices and Therapeutics Market Size by Homecare, 2020-2029
Table 1: Canada Diabetes Devices and Therapeutics Market Size by Value (US$ Million) 2020-2029 Table 2: Canada Diabetes Devices and Therapeutics Market Size by Diagnosis and Monitoring Devices, by Value (US$ Million), 2020-2029 Table 3: Canada Diabetes Devices and Therapeutics Market Size by Therapeutics, by Value (US$ Million) 2020-2029 Table 4: Canada Diabetes Devices and Therapeutics Market Size by Blood Glucose Monitoring Devices, by Value (US$ Million) 2020-2029 Table 5: Canada Diabetes Devices and Therapeutics Market Size by Insulin Delivery Devices, by Value (US$ Million) 2020-2029 Table 6: Canada Diabetes Devices and Therapeutics Market Size by Diabetes Management and Mobile Applications, by Value (US$ Million) 2020-2029 Table 7: Canada Diabetes Devices and Therapeutics Market Size by Artificial Pancreas Devices, by Value (US$ Million) 2020-2029 Table 8: Canada Diabetes Devices and Therapeutics Market Size by Self-Monitoring Blood Glucose Devices, by Value (US$ Million) 2020-2029 Table 9: Canada Diabetes Devices and Therapeutics Market Size by Continuous Blood Glucose Monitoring Devices, by Value (US$ Million) 2020-2029 Table 10: Canada Diabetes Devices and Therapeutics Market Size by Test Strips, by Value (US$ Million) 2020-2029 Table 11: Canada Diabetes Devices and Therapeutics Market Size by Lancets, by Value (US$ Million) 2020-2029 Table 12: Canada Diabetes Devices and Therapeutics Market Size by Insulin Pumps, by Value (US$ Million) 2020-2029 Table 13: Canada Diabetes Devices and Therapeutics Market Size by Insulin Pens, by Value (US$ Million) 2020-2029 Table 14: Canada Diabetes Devices and Therapeutics Market Size by Insulin Syringes, by Value (US$ Million) 2020-2029 Table 15: Canada Diabetes Devices and Therapeutics Market Size by Oral Anti-Diabetic Drugs, by Value (US$ Million), 2020-2029 Table 16: Canada Diabetes Devices and Therapeutics Market Size by Insulin, by Value (US$ Million), 2020-2029 Table 17: Canada Diabetes Devices and Therapeutics Market Size by Non-Insulin Injectable Drugs, by Value (US$ Million), 2020-2029 Table 18: Canada Diabetes Devices and Therapeutics Market Size by Combination Drugs, by Value (US$ Million), 2020-2029 Table 19: Canada Diabetes Devices and Therapeutics Market Size by Alpha-Glucosidase Inhibitors (US$ Million), 2020-2029 Table 20: Canada Diabetes Devices and Therapeutics Market Size by DPP-4 Inhibitors (US$ Million), 2020-2029 Table 21: Canada Diabetes Devices and Therapeutics Market Size by SGLT-2 Inhibitors (US$ Million), 2020-2029 Table 22: Canada Diabetes Devices and Therapeutics Market Size by Basal or Long-Acting, by Value (US$ Million), 2020-2029 Table 23: Canada Diabetes Devices and Therapeutics Market Size by Bolus or Fast-Acting, by Value (US$ Million), 2020-2029 Table 24: Canada Diabetes Devices and Therapeutics Market Size by Traditional Human Insulin Drugs, by Value (US$ Million), 2020-2029 Table 25: Canada Diabetes Devices and Therapeutics Market Size by Insulin Biosimilars, by Value (US$ Million), 2020-2029 Table 26: Canada Diabetes Devices and Therapeutics Market Size by GLP-1 Receptor Agonists, by Value (US$ Million), 2020-2029 Table 27: Canada Diabetes Devices and Therapeutics Market Size by Amylin Analogue, by Value (US$ Million), 2020-2029 Table 28: Canada Diabetes Devices and Therapeutics Market Size by Combination Insulin, by Value (US$ Million), 2020-2029 Table 29: Canada Diabetes Devices and Therapeutics Market Size by Oral Combination, by Value (US$ Million), 2020-2029 Table 30: Canada Diabetes Devices and Therapeutics Market Size by Subcutaneous, by Value (US$ Million), 2020-2029 Table 31: Canada Diabetes Devices and Therapeutics Market Size by Intravenous, by Value (US$ Million), 2020-2029 Table 32: Canada Diabetes Devices and Therapeutics Market Size by Others, by Value (US$ Million), 2020-2029 Table 33: Canada Diabetes Devices and Therapeutics Market Size by Type 2 Diabetes, by Value (US$ Million), 2020-2029 Table 34: Canada Diabetes Devices and Therapeutics Market Size by Type 1 Diabetes, by Value (US$ Million), 2020-2029 Table 35: Canada Diabetes Devices and Therapeutics Market Size by Online Pharmacies, by Value (US$ Million), 2020-2029 Table 36: Canada Diabetes Devices and Therapeutics Market Size by Hospital Pharmacies, by Value (US$ Million), 2020-2029 Table 37: Canada Diabetes Devices and Therapeutics Market Size by Retail Pharmacies, by Value (US$ Million), 2020-2029 Table 38: Canada Diabetes Devices and Therapeutics Market Size by Hospitals, by Value (US$ Million), 2020-2029 Table 39: Canada Diabetes Devices and Therapeutics Market Size by Diabetes Clinics, by Value (US$ Million), 2020-2029 Table 40: Canada Diabetes Devices and Therapeutics Market Size by Homecare, by Value (US$ Million), 2020-2029
Figure 1: Canada Diabetes Devices and Therapeutics Market Size by Value (US$ Million) 2020-2029 Figure 2: Canada Diabetes Devices and Therapeutics Market Share by Category (%), 2020-2029 Figure 3: Canada Diabetes Devices and Therapeutics Market Size by Diagnosis and Monitoring Devices, by Value (US$ Million), 2020-2029 Figure 4: Canada Diabetes Devices and Therapeutics Market Size by Therapeutics, by Value (US$ Million) 2020-2029 Figure 5: Canada Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices (%), 2020-2029 Figure 6: Canada Diabetes Devices and Therapeutics Market Size by Blood Glucose Monitoring Devices, by Value (US$ Million) 2020-2029 Figure 7: Canada Diabetes Devices and Therapeutics Market Size, by Insulin Delivery Devices, by Value (US$ Million) 2020-2029 Figure 8: Canada Diabetes Devices and Therapeutics Market Size by Diabetes Management and Mobile Applications, by Value (US$ Million) 2020-2029 Figure 9: Canada Diabetes Devices and Therapeutics Market Size, by Artificial Pancreas Devices, by Value (US$ Million) 2020-2029 Figure 10: Canada Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices (%), 2020-2029 Figure 11: Canada Diabetes Devices and Therapeutics Market Size by Self-Monitoring Blood Glucose Devices, by Value (US$ Million) 2020-2029 Figure 12: Canada Diabetes Devices and Therapeutics Market Size by Continuous Blood Glucose Monitoring Devices, by Value (US$ Million) 2020-2029 Figure 13: Canada Diabetes Devices and Therapeutics Market Size by Test Strips, by Value (US$ Million) 2020-2029 Figure 14: Canada Diabetes Devices and Therapeutics Market Size by Lancets, by Value (US$ Million) 2020-2029 Figure 15: Canada Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices (%), 2020-2029 Figure 16: Canada Diabetes Devices and Therapeutics Market Share by Insulin Pumps, by Value (US$ Million) 2020-2029 Figure 17: Canada Diabetes Devices and Therapeutics Market Share by Insulin Pens, by Value (US$ Million) 2020-2029 Figure 18: Canada Diabetes Devices and Therapeutics Market Share by Insulin Syringes, by Value (US$ Million) 2020-2029 Figure 19: Canada Diabetes Devices and Therapeutics Market Share by Therapeutics (%), 2020-2029 Figure 20: Canada Diabetes Devices and Therapeutics Market Size by Oral Anti-Diabetic Drugs, by Value (US$ Million), 2020-2029 Figure 21: Canada Diabetes Devices and Therapeutics Market Size by Insulin, by Value (US$ Million), 2020-2029 Figure 22: Canada Diabetes Devices and Therapeutics Market Size by Non-Insulin Injectable Drugs, by Value (US$ Million), 2020-2029 Figure 23: Canada Diabetes Devices and Therapeutics Market Size by Combination Drugs, by Value (US$ Million), 2020-2029 Figure 24: Canada Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs (%), 2020-2029 Figure 25: Canada Diabetes Devices and Therapeutics Market Size by Alpha-Glucosidase Inhibitors (US$ Million), 2020-2029 Figure 26: Canada Diabetes Devices and Therapeutics Market Size by DPP-4 Inhibitors (US$ Million), 2020-2029 Figure 27: Canada Diabetes Devices and Therapeutics Market Size by SGLT-2 Inhibitors (US$ Million), 2020-2029 Figure 28: Canada Diabetes Devices and Therapeutics Market Share by Insulin (%), 2020-2029 Figure 29: Canada Diabetes Devices and Therapeutics Market Size by Basal or Long-Acting, by Value (US$ Million), 2020-2029 Figure 30: Canada Diabetes Devices and Therapeutics Market Size by Bolus or Fast-Acting, by Value (US$ Million), 2020-2029 Figure 31: Canada Diabetes Devices and Therapeutics Market Size by Traditional Human Insulin Drugs, by Value (US$ Million), 2020-2029 Figure 32: Canada Diabetes Devices and Therapeutics Market Size by Insulin Biosimilars, by Value (US$ Million), 2020-2029 Figure 33: Canada Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs (%), 2020-2029 Figure 34: Canada Diabetes Devices and Therapeutics Market Size by GLP-1 Receptor Agonists, by Value (US$ Million), 2020-2029 Figure 35: Canada Diabetes Devices and Therapeutics Market Size by Amylin Analogue, by Value (US$ Million), 2020-2029 Figure 36: Canada Diabetes Devices and Therapeutics Market Share by Combination Drugs (%), 2020-2029 Figure 37: Canada Diabetes Devices and Therapeutics Market Size by Combination Insulin, by Value (US$ Million), 2020-2029 Figure 38: Canada Diabetes Devices and Therapeutics Market Size by Oral Combination, by Value (US$ Million), 2020-2029 Figure 39: Canada Diabetes Devices and Therapeutics Market Share by Route of Administration (%), 2020-2029 Figure 40: Canada Diabetes Devices and Therapeutics Market Size by Subcutaneous, by Value (US$ Million), 2020-2029 Figure 41: Canada Diabetes Devices and Therapeutics Market Size by Intravenous, by Value (US$ Million), 2020-2029 Figure 42: Canada Diabetes Devices and Therapeutics Market Size by Others, by Value (US$ Million), 2020-2029 Figure 43: Canada Diabetes Devices and Therapeutics Market Share by Type of Diabetes (%), 2020-2029 Figure 44: Canada Diabetes Devices and Therapeutics Market Size by Type 2 Diabetes, by Value (US$ Million), 2020-2029 Figure 45: Canada Diabetes Devices and Therapeutics Market Size by Type 1 Diabetes, by Value (US$ Million), 2020-2029 Figure 46: Canada Diabetes Devices and Therapeutics Market Share by Distribution Channels (%), 2020-2029 Figure 47: Canada Diabetes Devices and Therapeutics Market Size by Online Pharmacies, by Value (US$ Million), 2020-2029 Figure 48: Canada Diabetes Devices and Therapeutics Market Size by Hospital Pharmacies, by Value (US$ Million), 2020-2029 Figure 49: Canada Diabetes Devices and Therapeutics Market Size by Retail Pharmacies, by Value (US$ Million), 2020-2029 Figure 50: Canada Diabetes Devices and Therapeutics Market Share by End User (%), 2020-2029 Figure 51: Canada Diabetes Devices and Therapeutics Market Size by Hospitals, by Value (US$ Million), 2020-2029 Figure 52: Canada Diabetes Devices and Therapeutics Market Size by Diabetes Clinics, by Value (US$ Million), 2020-2029 Figure 53: Canada Diabetes Devices and Therapeutics Market Size by Homecare, by Value (US$ Million), 2020-2029
